Amaranth oil application for coronary heart disease and hypertension

Danik M Martirosyan1, Lidia A Miroshnichenko, Svetlana N Kulakova

  • 1Functional Foods Center, Dallas, TX, USA. ffc_usa@sbcglobal.net

Insights

Amaranth oil may benefit cardiovascular health by positively impacting cholesterol levels and cell membrane function. Further research is needed to confirm its therapeutic potential for cardiovascular disease patients.

Area of Science:

  • Nutritional Science
  • Biochemistry
  • Cardiovascular Health

Background:

  • Cardiovascular disease (CVD) is a leading cause of death, associated with risk factors like hyperlipidemia and hypertension.
  • Elevated cholesterol levels (LDL, total cholesterol) and low HDL cholesterol indicate increased CVD risk.
  • Dietary fatty acid composition influences CVD risk, with unsaturated fats being beneficial.

Purpose of the Study:

  • To investigate the potential cardiovascular benefits of amaranth oil.
  • To explore amaranth oil's effects on cholesterol biosynthesis and absorption.
  • To hypothesize amaranth oil's therapeutic role in cardiovascular disease.

Main Methods:

  • Review of existing literature on amaranth grain compounds (tocotrienols, squalene) and their effect on cholesterol.
  • Examination of studies on amaranth oil's impact on blood cholesterol levels in animal models.
  • Analysis of amaranth oil's previously demonstrated effects on cell membrane fluidity and stability.

Main Results:

  • Amaranth grain contains compounds that influence cholesterol biosynthesis and absorption.
  • Studies show amaranth oil can decrease blood cholesterol levels.
  • Amaranth oil has been shown to modulate and stabilize cell membranes.

Conclusions:

  • Amaranth oil's compounds and effects on cholesterol metabolism suggest potential cardiovascular benefits.
  • Its ability to modulate cell membrane fluidity may be crucial for its beneficial effects, particularly in hypertension.
  • Amaranth oil is hypothesized to be beneficial for patients with cardiovascular disease.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...